Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 1 to 10 of 177 total matches.
Guselkumab (Tremfya) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
treatment.
▶ Dosage: Induction: 200 mg IV at weeks 0, 4, and 8.
Maintenance: 100 mg SC at week 16, then q8 ...
The interleukin (IL)-23 antagonist guselkumab
(Tremfya – Janssen Biotech) has now been approved
by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was
approved earlier for treatment of plaque psoriasis
and psoriatic arthritis. Guselkumab is the third IL-23
antagonist to be approved in the US for treatment of
UC; risankizumab (Skyrizi) and mirikizumab (Omvoh)
were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8 doi:10.58347/tml.2025.1724d | Show Introduction Hide Introduction
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
vials 200 mg IV once, then 100 mg IV $1336.20
once/day3
Caspofungin – generic 50, 70 mg single-dose ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug to become available
in the US in more than 15 years for treatment of
systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4 doi:10.58347/tml.2024.1705d | Show Introduction Hide Introduction
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
caps
18, 35 mg caps
50 mg q8-12h (max 200 mg/day)
25 mg q6h (max 200 mg/day)
18 or 35 mg tid
Can ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
In Brief: Azmiro — A Single-Dose Injectable Formulation of Testosterone Cypionate
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
Usual Adult Dosage2 Cost3
Testosterone cypionate – generic 1, 10 mL vials (100, 200 mg/mL)4,5 50-400 mg ...
The FDA has approved Azmiro (Azurity), the first
injectable formulation of testosterone cypionate to
become available in single-dose vials and prefilled
syringes for treatment of males with conditions
associated with a deficiency or absence of endogenous
testosterone. Injectable testosterone cypionate has
been available in multidose vials (Depo-Testosterone,
and generics) for many years. Testosterone enanthate
(Xyosted) is available in prefilled autoinjectors for use
in adult men. No testosterone products are approved
for treatment of low testosterone levels due solely
to aging. All...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):44-5 doi:10.58347/tml.2025.1724b | Show Introduction Hide Introduction
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
)
Albuterol – generic of ProAir HFA (Teva) 90 mcg/inh HFA MDI (200 inh/unit3) 1-2 inh q4-6h PRN ≥4 yrs: 1-2 ...
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e192-5 doi:10.58347/tml.2024.1716b | Show Introduction Hide Introduction
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
Route Oral
Formulation 12.5, 25, 50, 100, 150, 200 mg tabs
Tmax 1-4 hours
Metabolism Glucuronidation ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
of 3 doses
of opicapone (5, 25, or 50 mg) once daily, 200 mg of
entacapone administered with each ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
;
10 mg/mL, 50 mg/5 mL
oral soln
Adult: 50-200 mg/d in 2
divided doses
...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Viloxazine ER (Qelbree) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Selective norepinephrine reuptake inhibitor
Formulation 100, 150, 200 mg extended-release capsules
Route ...
The FDA has approved viloxazine extended-release
capsules (Qelbree – Supernus) for treatment of
attention-deficit/hyperactivity disorder (ADHD) in
children 6-17 years old. Viloxazine is the second
selective norepinephrine reuptake inhibitor to be
approved in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
)
generic – single dose vials
17 mcg/inh
200 mcg/mL soln
HFA MDI (200 inh/unit)
Nebulizer5
2 inh qid ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction